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Abstract
Pompe disease is a metabolic myopathy that is caused by glycogen accumulation as a result of deficiency of the
lysosomal enzyme acid alpha glucosidase (GAA). Previously, we showed that adult muscle stem cells termed satellite cells
are present at normal levels in muscle from patients with Pompe disease, but that these are insufficiently activated to
repair the severe muscle pathology. Here we characterized the muscle regenerative response during disease progression
in a mouse model of Pompe disease and investigated the intrinsic capacity of Gaa−/− satellite cells to regenerate muscle
damage. Gaa−/− mice showed progressive muscle pathology from 15 weeks of age as reflected by increased lysosomal
size, decreased fiber diameter and reduced muscle wet weight. Only during the first 15 weeks of life but not thereafter,
we detected a gradual increase in centrally nucleated fibers and proliferating satellite cells in Gaa−/− muscle, indicating a
mild regenerative response. The levels of Pax7-positive satellite cells were increased in Gaa−/− mice at all ages, most likely
as result of enhanced satellite cell activation in young Gaa−/− animals. Surprisingly, both young and old Gaa−/− mice
regenerated experimentally-induced muscle injury efficiently as judged by rapid satellite cell activation and complete
restoration of muscle histology. In response to serial injury, Gaa−/− mice also regenerated muscle efficiently and
maintained the satellite cell pool. These findings suggest that, similar to human patients, Gaa−/− mice have
insufficient satellite cell activation and muscle regeneration during disease progression. The initial endogenous satellite
cell response in Gaa−/− mice may contribute to the delayed onset of muscle wasting compared to human patients.
The rapid and efficient regeneration after experimental muscle injury suggest that Gaa−/− satellite cells are functional
stem cells, opening avenues for developing muscle regenerative therapies for Pompe disease.
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Introduction
Pompe disease is a metabolic myopathy that is caused by
deficiency of acid alpha glucosidase (GAA), a lysosomal
enzyme responsible for the degradation of glycogen [38].
Pompe patients develop progressive skeletal muscle weak-
ness due to lysosomal expansion, followed by lysosomal
disruption and myofiber death. Affected muscles in-
clude those involved in mobility and respiration, and as
a result Pompe patients become wheelchair and ventila-
tor dependent [59]. The most severe classic infantile
form of Pompe disease is caused by complete absence
of GAA enzyme activity and results in death within the
first year of life, if left untreated [52]. In milder forms
of Pompe disease, residual GAA activity exists, and pa-
tients develop symptoms later in life [17, 54]. A treat-
ment for Pompe disease is available in the form of enzyme
replacement therapy (ERT). ERT improves muscle function
and prolongs survival [2, 4, 21, 24, 33, 36, 37, 51, 57], but
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the heterogeneous response among patients has urged the
development of alternative treatment options [5].
Skeletal muscle has the capacity to regenerate upon
damage. Genetic ablation of Pax7-expressing cells in
mice has shown that this process is dependent on adult
muscle stem cells termed satellite cells [25, 40]. In
healthy muscle, satellite cells reside in a quiescent state
located in between the sarcolemma and the basal lamina
[30]. Upon muscle damage, satellite cells become acti-
vated and enter the cell cycle. Proliferating satellite cells
have two fates: to repair muscle fibers, or to replenish
the satellite cell pool [7]. Given the regenerative proper-
ties of skeletal muscle a major unresolved question in
the field remains why satellite cells are apparently unable
to efficiently repair disease-induced muscle damage.
Several explanations have been proposed, including ex-
haustion of the satellite cell pool [39] or intrinsic failure
of satellite cells to regenerate muscle [3, 10]. For ex-
ample, in Duchenne Muscular Dystrophy, both satellite
cell depletion/exhaustion and intrinsic failure of satellite
cells to regenerate have been proposed [10, 39]. Previ-
ously, we have analyzed muscle biopsies from patients
with Pompe disease [41]. Our study demonstrated a lack
of muscle regeneration to the severe damage observed in
biopsies from Pompe patients, even in those from severely
affected classic infantile patients. We found that satellite
cells were present at similar levels as in healthy controls,
arguing against satellite cell depletion in Pompe disease
[41]. However, satellite cells were mostly inactive, in agree-
ment with the lack of detectable muscle regeneration.
The maintenance of the satellite cell pool in patients
with Pompe disease suggested the possibility that en-
dogenous satellite cells represent a therapeutic target for
Pompe disease. A prerequisite for this idea is that satel-
lite cells are intrinsically capable of regenerating muscle.
So far, this remained unclear given the low level of
muscle regeneration in Pompe patients. To address this,
in the present study we used two knockout mouse
models for Pompe disease on different genetic back-
grounds [6, 35]. We characterized the satellite cell re-
sponse in Gaa−/− mice, and related this to myofiber
pathology. We then applied a single and serial external
injury and characterized muscle regeneration and the
satellite cell response. Our results indicate that Gaa−/−
mice have activated satellite cells and low levels of
muscle regeneration only during the first 15 weeks of
life. Single and serial experimentally induced muscle in-
juries provoked efficient satellite cell activation and
muscle regeneration in Gaa−/− mice. These results indi-
cate that satellite cells in Gaa−/− mice have the intrinsic
capacity to efficiently regenerate muscle and self-renew.
These findings suggest that satellite cell activation may
be explored as a therapeutic strategy to promote muscle
regeneration in Pompe disease.
Material and methods
Mice and animal procedures
Age-matched wildtype and Gaa−/− animals on an FVB/
N [6] inbred, or mixed C57/Bl6 and 129/Sv [35] back-
ground were used between 2 and 70 weeks of age. Wild
type FVB/N breeder animals were obtained from Envigo,
and were used to start a colony that is maintained at the
Erasmus MC animal facility. Gaa−/−(FVB/N) animals
had been generated previously by targeted disruption of
exon 13 of the Gaa gene [6]. We performed homozy-
gous breedings to generate both the wildtype and Gaa−/−
animals in the FVB/N background during the duration of
this project. Wildtype control and Gaa−/− animals in the
mixed C57/Bl6 and 129/Sv background were obtained as
littermates from heterozygous breedings and maintained
at the Cardarelli Hospital’ s Animal Facility (Naples, Italy).
Gaa−/−(Bl6) animals obtained by insertion of a neo cas-
sette into exon 6 of the Gaa gene [35] were purchased
from Charles River Laboratories (Wilmington, MA). All
mice in experiment were housed under a light–dark cycle
(12 h) and under defined pathogen-free conditions, with
access to food and water ad libitum.
Muscle injury was induced by intramuscular injection
of 1.2% (w/v in PBS) BaCl2 or cardiotoxin (CTX; 10 μmol
in PBS). Animals were allowed to recover for the time
indicated in the figures. Serial injury experiments were
performed by injecting BaCl2, as described above, three
times at monthly intervals into the Tibialis Anterior
(TA) muscle. Three weeks after the last BaCl2 injection
the animals were sacrificed for tissue collect.
At the end of experiments animals were sacrificed by
cervical dislocation during daytime without a fixed time-
point. Tissue wet weight was determined by weighing
freshly dissected tissue that was blotted dry. All animal
experiments were approved by the local and national
animal experiment authorities in compliance with the
European Community Council Directive guidelines (EU
Directive 86/609), regarding the protection of animals
used for experimental purposes, and according to Insti-
tutional Animal Care and Use Committee (IACUC)
guidelines for the care and use of animals in research.
The study was approved by the local and national au-
thorities in the Netherlands and Italy, respectively. All
procedures with the animals were performed with the
aim of ensuring that discomfort, distress, pain, and in-
jury would be minimal.
Determination of glycogen levels
To measure tissue glycogen concentrations 20 30 μm
cryosections were collected for each sample. The sec-
tions were homogenized using 5 mm stainless steel
beads (Qiagen NV) in the Qiagen Retsch MM300 Tis-
sueLyser (Qiagen NV) at 30 Hz for 5 min. Glycogen was
quantified in tissue supernatant by measuring the
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amount of glucose released from glycogen after conver-
sion by amyloglycosidase and amylase (Roche Diagnostics)
for 1 h as previously described [58]. Spectral absorbance
of the products was measured on a Varioskan spec-
trometer (Thermo Scientific) at 414 nm. Results from
the glycogen measurements were normalized for pro-
tein content using the Pierce BCA protein assay kit
(Thermo Scientific).
Histology and immunofluorescent analyses
Hematoxylin and Eosin (HE) staining and Masson’s tri-
chrome staining were performed using routine histology
protocols as described previously [41]. For immunostain-
ing, Tissue-Tek OCT-embedded tissue was snap-frozen
in liquid nitrogen-cooled isopentane. 10 μm cryosections
were cut and fixated in ice-cold aceton. A heated antigen
retrieval procedure with 10 mM citrate buffer was used
for the detection of Pax7. Sections were stained essen-
tially as described previously [41], but using the M.O.M.
kit from Vector laboratories for blocking endogenous
mouse immunogens. Primary antibodies used were
eMyHC (F1.652; DSHB; 1:300), Ki67 (Ab15580; Abcam;
1:50), laminin (L9393; Sigma; 1:500 or LS-C (6142; LS
BIO; 1:500)), Lamp1 (Ab24170; Abcam; 1:150). Hoechst
(H33258, Sigma) was used at 1 μg/ml. To detect cen-
trally nucleated myofibers aceton-fixed 10 μm cryosec-
tions were stained for laminin using a primary antibody
and Hoechst for nuclei, as described above, and imaged
by fluorescent microscopy.
Image acquisition and analysis
Histological sections were scanned with 4x and 20x ob-
jectives on a Hamamatsu NanoZoomer 2.0 (Hamamatsu
Photonics). Images were analyzed using NDP view soft-
ware (NDP View 1.2.31 Eng, Hamamatsu Photonics).
Sections used for immunofluorescence were scanned on
Zeiss LSM700 (Carl Zeiss B.V.) using tile-scan modality
with a 20x objective. Image analysis and processing was
performed using Fiji (fiji.sc/Fiji) and Adobe Photoshop.
Quantification of myofiber diameter was performed
using cross sections by measuring the longest diagonal
(in μm) in at least 100 fibers per sample, randomly se-
lected throughout the whole section.
Flow cytometry
Preparation of limb muscle for flow cytometric analysis
was adapted from Liu et al. [28]. In short, dissected tis-
sue was minced thoroughly to small pieces in F10
medium (Lonza) containing collagenase II (750 U/ml;
Fisher Scientific) using scalpels. Minced tissue was disso-
ciated for 70 min in F10 medium containing 750 U/ml
collagenase II), then for 30 min in F10 medium contain-
ing collagenase II (100 U/ml) and dispase (1.1 U/ml;
Fisher Scientific). Cell suspensions were filtered over a
40 μM cell strainer (Falcon) and a small sample was re-
trieved to determine total mononuclear cell count using
a hematocytometer. The cell suspensions were stained
with CD31-APC (1:100), CD45-APC (1:100), Sca1-FITC
(1:100) and Vcam-biotin (1:50) primary antibodies. Vcam
was visualized using streptavidin-PECY7 (1:100). All
antibodies for flowcytometry were derived from BD Bio-
sciences. Cell viability was determined by staining with
1 μg/ml Hoechst 33258 (Sigma). Samples were analyzed
on a BD-ARIAIII (BD biosciences).
Statistical analysis
For all experiments normal distribution of data was de-
termined based on calculated residuals. Normally dis-
tributed data from two groups was tested using a
2-tailed t-test. For experiments with three groups or
more a one-way ANOVA of independent samples with
Tukey or Games-Howell Post Hoc multiple correction
(depending on homogeneity of variance) was used.
Non-normal distributed data was statistically tested
using a Mann-Whitney non-parametric test (two groups)
or a Kruskal-Wallis test of independent samples with
Bonferoni multiple comparison for three or more
groups. For all tests a p-value less than 0.05 was consid-
ered significant. Data was analyzed using IBM SPSS sta-
tistics version 25.
Results
Characterization of muscle pathology during disease
progression in Gaa−/− mice
Previous work has shown that Gaa−/− non-inbred mice
(on FVB or C57/Bl6 backgrounds mixed with the 129
background) display hallmarks of Pompe disease, in-
cluding progressive skeletal muscle wasting and glyco-
gen accumulation. We now performed a more in-depth
quantitative analysis of the timing of myofiber path-
ology and muscle wasting in FVB inbred mice (indicated
as Gaa−/−(FVB)). Key results throughout this report
were confirmed on Gaa−/− mice in the C57/Bl6
non-inbred background (indicated as Gaa−/−(Bl6)).
Glycogen accumulation was detected in Tibialis Anterior
(TA) muscle from Gaa−/− mice at the age of 2 weeks, and
increased further during aging (Fig. 1a). Maximal glycogen
levels were reached in animals of about 25 weeks and
remained stable thereafter. To examine abnormalities in
lysosomal size, immunofluorescent staining of Lamp1 was
performed (Fig. 1b). No Lamp1 staining was detected in
TA muscle sections from wild type mice due to the small
size of lysosomes. In Gaa−/− muscle, TA sections showed a
punctated Lamp1 pattern from 15 weeks of age and on-
wards indicating increased lysosomal size. The number of
Lamp1-positive spots per fiber did not increase further in
older Gaa−/− mice (Fig. 1b-c). TA wet weight was reduced
in Gaa−/− mice compared to wild type mice, starting at
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25 weeks of age, and decreased further with age with 54%
at 70 weeks of age (Fig. 1d). Histological analysis of TA sec-
tions showed a decrease in fiber diameter in the Gaa−/−
mice compared to wild type mice that started between 15
and 25 weeks of age (Fig. 1e-f). Fiber diameter distribution
was determined by quantifying the number of fibers in dif-
ferent fiber size categories. This showed enrichment of
smaller-sized fibers in muscles of 15-week Gaa−/− mus-
cles relative to those from age-matched wild type ani-
mals (Additional file 1: Figure S1A). Gaa−/− Quadriceps
Femoris (QF) muscles at 3 months of age in the C57/
Bl6 non-inbred background also displayed enrichment
for smaller fibers (Additional file 1: Figure S1B). These
results indicate that Gaa−/−(FVB) mice show progres-
sive myofiber pathology reminiscent of Pompe disease
starting at 15 weeks of age.
Modest and transient muscle regeneration during disease
progression in Gaa−/− mice
To assess whether Gaa−/− (FVB) mice regenerate TA
muscle in response to Pompe disease-induced muscle
pathology, we first performed immunofluorescent staining
of embryonic Myosin Heavy Chain (eMyHC), a marker
for actively regenerating myofibers [42] (Fig. 2a). Few
small-sized eMyHC-positive fibers were detected in mus-
cles from Gaa−/− animals between 2 and 60 weeks of age
(< 0.7% of myofibers). Representative examples are shown
in Fig. 2a. A similar result was obtained for Gaa−/− animals
in the C57/Bl6 non-inbred background (Additional file 2:
Figure S2A). Muscle from wild type mice did not show
eMyHC-positive fibers in either background.
In murine muscle, regenerated myofibers can be iden-
tified by the presence of centrally located nuclei [27].
We used Hoechst to stain nuclei in TA sections (Fig. 2b),
and this showed an increased percentage of fibers with
central nuclei in Gaa−/− TA muscle from 15 weeks of age
(Fig. 2c). At 25 weeks of age, the percentage of centrally nu-
cleated fibers reached a plateau of 15% that remained stable
until 60 weeks of age. In comparison, published results in
the mdx mouse, a model for Duchenne Muscular Dys-
trophy, showed that already at 12 weeks of age > 70% of
lower limb muscle myofibers were centrally nucleated [1],
indicating that the disease-mediated muscle-regenerative
response is relatively mild in Gaa−/− muscle. Modest
central nucleation was also detected in GAS muscle
at 3 month-old Gaa−/−(Bl6) mice (Additional file 2:
Figure S2B). We conclude that Gaa−/− mice have a
relatively mild and limited muscle regenerative re-
sponse during disease progression.
Satellite cells are increased in number but are only
transiently activated during disease progression in Gaa−/−
limb muscle
Genetic ablation of Pax7-expressing cells demonstrated
that satellite cells are indispensable for muscle regener-
ation [25, 40]. Satellite cells are marked by expression of
Pax7, which is a master transcription factor that regu-
lates survival and expression of myogenic transcription
factors involved in muscle differentiation and regeneration
[23, 43]. To assess the consequence of Gaa-deficiency and
the related muscle pathology on satellite cell dynamics, we
performed immunofluorescent staining of Pax7 in TA sec-
tions (Fig. 3a). The number of Pax7-positive cells was sta-
bly increased in Gaa−/− TA muscle relative to wild type
muscle at all ages tested (2–60 weeks), and varied between
20 and 50 Pax7-positive cells/mm2 (Fig. 3b). The increase
in Pax7-positive cells in Gaa−/− muscle was equally pro-
nounced when expressed as satellite cell per myofiber,
with a ~ 5 fold increase at 15 weeks and ~ 7.1 fold increase
at 25 week animals (Additional file 3: Figure S3), indicat-
ing that the difference in satellite cell density was inde-
pendent of changes in fiber diameter.
The number of Pax7-positive cells in wild type TA
muscle decreased from 8 to 2 Pax7-positive cells/mm2
during the same period (Fig. 3b). To confirm increased sat-
ellite cell levels in Gaa−/− mice, we analysed the number of
satellite cells by flow cytometry using a satellite cell surface
profile based on expression of Vcam [28] (Additional file 4:
Figure S4A). Using this profile we could detect a > 93%
pure population of Pax7-positive cells (Additional file 4:
Figure S4B). The number of Vcam-positive cells was stably
increased in Gaa−/− TA muscle between 15 and 70 weeks
of age relative to wild type TA muscle (Additional file 4:
Figure S4C). Satellite cell numbers were also increased in
(See figure on previous page.)
Fig. 1 Characterization of lysosomal and muscle wasting pathology during disease progression in Gaa−/− mice. a. Glycogen accumulation.
Glycogen levels were measured biochemically in TA muscles at the indicated ages. b. Lysosomal pathology. Immunofluorescent analysis of TA
sections using a Lamp1 antibody (in green). Representative images are shown. The basal lamina was stained using a Laminin antibody (in red).
Nuclei were stained with Hoechst (in blue). Black and white images of Lamp1 staining are included for better visualization. c. Quantification of
the number of Lamp1-positive spots per fiber from B. Data are from two TA muscles derived from two different animals per genotype per
timepoint, and are expressed as mean ± SD. ***p < 0.001. d. Wet weight of TA muscles. Each dot represents TA wet weight from one muscle of
one animal. Means ± SD are indicated as lines (n = 4–12 animals per genotype per timepoint). *p < 0.05 and ***p < 0.001. e. HE staining of TA
sections. Representative images are shown. f. Quantification of fiber size from E. Data from individual mice are plotted (n = 2–4 animals per
genotype per timepoint). Means ± SD are indicated. *p < 0.05 and **p < 0.01
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Gaa−/−muscle in the C57/Bl6 non-inbred background as
shown by immunofluorescent analysis of Pax7-positive
cells in 3 months old gastrocnemius (GAS) muscles from
WT(Bl6) and Gaa−/−(Bl6) mice (Additional file 5: Figure
S5A-B). We also detected increased expression of Pax7
protein by immunoblotting of Gaa−/−(Bl6) GAS muscle
(Additional file 5: Figure S5C).
Upon activation, satellite cells proliferate in order to re-
generate muscle and replenish the satellite cell pool. To as-
sess whether satellite cells in Gaa−/− mice were activated in
response to muscle pathology, we analysed co-expression
of Pax7 and the proliferation marker Ki67 by immunofluor-
escent analysis (Additional file 6: Figure S6). In TA muscles
from young Gaa−/− mice up to 15 weeks of age ± 5% of sat-
ellite cells were Ki67-positive, while in older Gaa−/− mice
the Pax7-positive cells were Ki67-negative (Fig. 3c). In wild
type mice, Pax7-positive cells were Ki67-negative at all ages
tested. These results indicate that while satellite cell num-
bers were increased in Gaa−/− mice of all ages, satellite cell
activation was only observed during the first 15 weeks. In
older mice activated satellite cells were absent.
Gaa−/− mice efficiently regenerate muscle after
experimental injury
Similar to human Pompe patients, Gaa−/− mice insuffi-
ciently regenerated disease-induced muscle damage. To
determine whether this is an intrinsic property of Gaa−/−
satellite cells or caused by compromised satellite cell activa-
tion, we induced muscle injury using BaCl2 injection
(Fig. 4a). BaCl2 induces myofiber degeneration but leaves
satellite cells sufficiently unharmed to allow regeneration
[18]. BaCl2 was injected into TA muscles in 10, 25, or
40 weeks-old mice, and muscle regeneration was examined
at 15 days post injury (DPI) (Fig. 4a). Gaa−/− mice from all
three age groups efficiently regenerated TA muscle upon
injury, as judged by histological analysis of HE-stained tis-
sue sections (Fig. 4b). At 15 DPI, regeneration was com-
pleted in Gaa−/− mice of all three age groups while the wild
type muscle was still in the process of regenerating damage.
Quantification of the fiber diameter before and after the in-
jury confirmed these observations (Fig. 4c). To extend these
results, we followed regeneration for up to 100 DPI using
15 week-old mice (Fig. 4d). As judged by morphology,
A B
C
Fig. 2 Gaa−/− mice display modest and transient muscle regeneration during disease progression. a. eMyHC expression. Immunofluorescent staining
of TA sections using a MyHC antibody (in red). Representative images are shown. The basal lamina was stained using a Laminin antibody (in green).
Nuclei were stained with Hoechst (in blue). Black and white images of eMyHC staining are included for better visualization. b. Central nucleated fibers.
Representative images of TA sections stained with Laminin (in red) and Hoechst (in white). c. Quantification of central nucleated fibers from B. Data
represent means ± SD (n = 2–3 muscles from at least 2 different animals per genotype per timepoint). *p < 0.05. **p < 0.01 and ***p < 0.001
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muscle regeneration was complete in Gaa−/− mice at 15
DPI in Gaa−/− mice, and between 30 and 60 DPI in wild
type mice (Fig. 4e). Quantification of fiber diameter con-
firmed these observations (Fig. 4f). To examine the devel-
opment of chronic tissue fibrosis that may result from
incomplete regeneration as is observed in dystrophic
muscle [9], we performed trichrome staining on regener-
ated muscle. This showed some trichrome-positive areas at
time points before regeneration was completed in animals
of both genotypes reflecting the transient expansion of
fibro/adipogenic progenitors that is part of normal muscle
regeneration [20] (Additional file 7: Figure S7). At 15 DPI
little or no trichrome staining was detected in Gaa−/− or
wild type mice at 10, 15, or 40 weeks of age (Additional file 8:
Figure S8), suggesting successful tissue remodelling and ab-
sence of fibrotic muscle tissue replacement. In mice in the
C57/Bl6 non-inbred background, injury was induced using
cardiotoxin (CTX) injection into Quadriceps Femoris (QF)
muscle at 3 months and 11 months of age, or into the GAS
muscle at 3 months of age. All these tissues showed effi-
cient regeneration in Gaa−/− mice at similar efficiencies
compared to wild type mice, as judged by morphology
(Additional file 9: Figure S9). We conclude that Gaa−/−
mice have efficient intrinsic capacity to regenerate muscle
after experimentally-induced injury.
Satellite cell response in Gaa−/− mice after experimental
injury
To determine whether the efficient muscle regeneration
upon induced injury in Gaa−/− mice is accompanied by
satellite cell activation, we quantified the number of
Pax7-positive and Pax7/Ki67 double-positive cells at sev-
eral time points following BaCl2 injection in the TA
muscle (Fig. 5a-b). In both Gaa−/− and wild type mice,
the number of Pax7-positive cells was transiently and
strongly induced upon injury. In Gaa−/− mice, satellite
cell numbers were already increased at 3 DPI, peaked at
5 DPI, and then slowly returned to pre-injury numbers
during 7–60 DPI (Fig. 5c). Wild type mice showed
slightly slower kinetics, with increased satellite cell num-
bers that started increasing at 5 DPI and peaked at 9–11
DPI, and slowly returned to pre-injury levels during 11–
100 DPI. The kinetics of the number of Pax7/Ki67
double-positive cells paralleled those of Pax7-single posi-
tive cells in both Gaa−/− and wild type mice (Fig. 5d).
In the same experiment, active muscle regeneration
was examined using immunofluorescent staining of
eMyHC (Fig. 5e). The kinetics of eMyHC expression in
Gaa−/− mice paralleled the changes in number of Pax7-
expressing cells after injury (Fig. 5f; compare with Fig. 5c).
Together, these data show that the efficient regenerative
response of Gaa−/− muscle after BaCl2-induced injury is
mediated by a rapid satellite cell response and further
confirms that Gaa−/− satellite cells are not functionally
compromised.
Gaa−/− satellite cells regenerate muscle and self-renew
after serial injury
Gaa−/− mice showed efficient satellite cell-mediated
muscle regeneration upon a single induced injury. To
determine if Gaa−/− satellite cells can self-renew after in-
jury, which is essential for long-term muscle regener-
ation, we performed a serial injury experiment using
BaCl2 (Fig. 6a). Three consecutive injuries were applied
at 4 week intervals to the same TA muscles and animals
were allowed to regenerate in between injuries. At the
end of the experiment, 3 weeks after the last injury
(mice were 51 weeks of age at this timepoint), mice were
sacrificed and TA muscles were analysed. Histological
analysis of HE-stained tissue sections showed complete
regeneration from the serial injuries in both Gaa−/− and
wild type muscle (Fig. 6b). Quantification of fiber diam-
eter showed full restoration of fiber diameter in Gaa−/−
mice 3 weeks after the third injury (Fig. 6c). In wild type
mice, fiber diameter was not yet fully restored at this time
point, consistent with the slower kinetics after a single in-
jury (Fig. 6c, see also Fig. 4f). Therefore the parameters of
this experiment did not allow to fully assess the capacity
of wild type mice to regenerate after serial injury. The
number of Pax7-positive cells in three-times regenerated
Gaa−/− muscle was, although slightly lower, not signifi-
cantly different from satellite cell levels in pre-injury mus-
cles or in muscles at 60 weeks of age (Fig. 6d). In wild
type mice, the number of Pax7-positive cells was still en-
hanced at 3 weeks after the third injury, in line with the
slower regeneration kinetics after a single injury (see
Fig. 4f ). The levels of Pax7/Ki67 double-positive cells at
3 weeks after the third injury were very low in both
Gaa−/− and wild type TA muscle, consistent with their
levels at 3 weeks after a single injury (compare with
(See figure on previous page.)
Fig. 3 Satellite cells are increased in number but are only transiently activated during disease progression in Gaa−/− limb muscle. a. pax7 expression.
Immunofluorescent (IF) staining of TA sections using a Pax7 antibody (in red). Representative images are shown. The basal lamina was stained using a
Laminin antibody (in green). Nuclei were stained with Hoechst (in blue). Black and white images of Pax7 staining are also shown for better visualization.
Zooms of selected areas (white squares) are shown below the entire sections. b. Quantification of the number of Pax7-positive cells/mm2 from A. Data
are means ± SD from 2 muscles derived from 2 different animals per genotype per timepoint. *p < 0.05. **p < 0.01 and ***p < 0.001. c. Quantification of
the number of Pax7/Ki67 double-positive cells by immunofluorescent staining of TA sections using Pax7 and Ki67 antibodies. Representative stainings are
shown in Additional file 5: Figure S5. Data represent means ± SD from 2 TA muscles derived from 2 different animals. *p < 0.05
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Fig. 5d). This showed that also after repeated injury,
satellite cells in Gaa−/− TA muscle returned within a
normal timeframe to their quiescent state. We conclude
that Gaa−/− mice have a robust capacity to regenerate
muscle via satellite cells even after repeated injury and
that Gaa−/− satellite cells retain the capacity to self-renew
upon injury.
Discussion
In this study, we have used mouse models for Pompe
disease to assess the muscle regenerative capacity of sat-
ellite cells. We first determined the timing of muscle
pathology, and found the following sequence of events:
glycogen accumulation (starting at 2 weeks), enlarged ly-
sosomes (starting at 15 weeks of age), reduced fiber
diameter (starting at 15–25 weeks of age), and reduced
wet weight (starting at 25 weeks of age). Gaa-deficient
mice display a mild muscle regenerative response shortly
after birth up to 25 weeks of age, indicated by a gradual in-
crease in central nucleation, detection of some eMyHC-
positive myofibers and low-level satellite cell activation.
This correlated with the detection of proliferating satellite
cells during this period, but not thereafter. Satellite cell
proliferation during the first 15 weeks of age resulted in
stably increased levels of satellite cells in animals up to at
least 60 weeks of age. Induced muscle injury in Gaa−/−
mice using BaCl2 or CTX resulted in very efficient satellite
cell response and muscle regeneration. In addition, Gaa−/−
muscle regenerated completely after three consecutive
rounds of injury and regeneration, indicating that Gaa−/−
satellite cells are capable of self-renewal. These results in-
dicate that, similar to human Pompe patients, Gaa−/−
mice lack an efficient muscle regenerative response during
disease progression but maintain the satellite cell pool des-
pite the developing muscle damage. Importantly, satellite
cells in mice with Pompe disease have the intrinsic cap-
acity to efficiently regenerate after damage, suggesting that
the lack of a satellite cell response in Pompe disease is
caused by deficient satellite cell activation.
The mouse models for Pompe disease offers the op-
portunity to study the early stages of disease onset and
to link these to the muscle regenerative response. We
have used an inbred FVB strain as well as Gaa−/− mice
on a mixed C57/Bl6 and 129/Sv background to investi-
gate this. The key aspects of muscle regeneration activity
in Gaa-deficient muscle were observed in both these
mouse models, including the mild regenerative response
during disease progression, reflected by the gradual in-
crease in central nucleation and detection of few
eMyHC-expressing myofibers, together with increased
satellite cell levels and an efficient regenerative response
after experimental injury. This strengthens the conclu-
sion that the regenerative response during Pompe dis-
ease progression is inefficient and disturbed. To address
this point in more detail, we used Gaa−/− animals in the
FVB background to extensively characterize the regener-
ation response as well as the ability to regenerate after
(serial) experimental injury. This extended on earlier re-
ports [6, 35] that the Gaa−/− mouse models develops
symptoms more slowly compared to classic infantile
Pompe patients, even though in both human and mouse
cases, Gaa activity was completely disrupted. Classic in-
fantile Pompe patients show symptoms shortly after
birth [55] and these include generalized muscle weak-
ness evident by decreased muscle tone and strength.
Muscle biopsies from classic infantile Pompe patients
show severely damaged muscle fibers [41, 48, 56]. At the
same time, satellite cells in classic infantile patients are
not activated and muscle regeneration is undetectable
[41]. In contrast, Gaa−/− mice developed cellular path-
ology at adulthood, starting at 15–25 weeks of age, as in-
dicated by increased lysosomal size and decreased fiber
diameter and wet weight. Interestingly, satellite cells in
Gaa−/− mice were activated until the age of 15 weeks, as
indicated by the detection of Pax7-positive satellite cells
that co-express Ki67. Proliferating satellite cells were not
detected in older animals. This may suggest that the en-
dogenous satellite cells response in the first 15 weeks
after birth contributed to the delayed onset of muscle
wasting in Gaa−/− mice compared to that in human clas-
sic infantile patients. It is interesting to speculate that a
modest satellite cells response and muscle regeneration
activity may prevent the development of muscle fiber
pathology. Future work is required to test this notion.
It remains unclear why the satellite cell response in
Pompe disease is so modest (mouse) or not detectable
(human). In certain other neuromuscular disorders, sat-
ellite cells and muscle regeneration have a markedly dif-
ferent behaviour. For example, in Duchenne Muscular
Dystrophy, studies using the mdx mouse model or the
(See figure on previous page.)
Fig. 4 Gaa−/−mice regenerate muscle efficiently after experimental injury. a. Schematic representation of the injury experiment. Black arrows
indicate the time at which TA muscles were collected for analysis, the red arrow indicates the time of injury. b. HE staining of TA sections before
(Uninjured, 0 days post injury (DPI)) and at 15 days DPI with BaCl2 at three ages. Representative images are shown. c. Quantification of fiber
diameter from (b). d. Schematic representation of injury experiment with a longer follow up after injury. Black arrows indicate the time at which
TA muscles were collected for analysis, red arrow indicate the time of injury. e. HE staining of TA sections of the injury experiment with long follow-up.
Representative images are shown. f. Quantification of fiber diameter from E. Data in C and F are means ± SD from at least 3 muscles derived from 2 or
more different animals. *p < 0.05; **p < 0.01 and ***p < 0.001
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Fig. 5 (See legend on next page.)
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Fig. 5 Rapid satellite cell response in Gaa−/− mice after experimental injury. a. Experimental schedule. Black arrows indicate the time at which TA
muscles were collected for analysis, the red arrow indicates the time of injury. b. pax7 expression. Immunofluorescent (IF) staining of TA sections
using a Pax7 antibody (in red). Representative images are shown. The basal lamina was stained using a Laminin antibody (in green). Nuclei were
stained with Hoechst (in blue). Black and white images of Pax7 staining are included for better visualization. c. Quantification of the number of
Pax7-positive cells/mm2 from B. Data are means ± SD from at least 2 muscles from 2 different animals. d. As C, but now for the number of Pax7/
Ki67 double-positive cells/mm2. e. eMyHC expression at 5 DPI. Immunofluorescent staining using a MyHC antibody (in red). Representative
images are shown. The basal lamina was stained using a Laminin antibody (in green). Nuclei were stained with Hoechst (in blue). Zooms of
selected areas (white squares) are shown on the right. f. Quantification of the eMyHC-positive area in TA sections. Data are means ± SD from at
least 2 muscles derived from 2 different animals
E
D
C
A B
Fig. 6 Gaa−/− satellite cells regenerate muscle and self-renew after serial injury. a. Experimental schedule. Black arrows indicate the time at which
TA muscles were collected for analysis, red arrows indicate the time of injury. b. HE staining of TA sections before and 3 weeks after the third
injury. Representative images are shown. c. Quantification of fiber diameter in WT (left) and Gaa−/− (right) TA muscle after serial injury from (b).
d. Quantification of the number of Pax7-positive cells by immunofluorescent staining of TA sections using a Pax7 antibody in WT (left) and Gaa−/−
(right) TA muscle after serial injury. e. Quantification of the number of Pax7/Ki67 double-positive cells by immunofluorescent staining of TA sections
using Pax7 and Ki67 antibodies in WT (left) and Gaa−/− (right) TA muscle after serial injury. Data in c-e are means ± SD from at least 2 muscles derived
from 2 different animals. For comparison with levels of indicated parameter in uninjured age-matched TA muscles, values at 40 weeks of age (to
compare with the start of the experiment) and at 60 weeks of age (to compare with the end of the experiment) are included in (c-e)
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more severe mdx/utrophin double-knockout model have
reported both exhaustion and depletion of satellite cells
as result of continuous satellite cell activation during
disease progression [29, 39]. In muscle biopsies from
Duchenne patients, elevated muscle regeneration activity
is observed [8, 22, 31, 39, 41]. Increased satellite cell ac-
tivation is attributed to sarcolemmal fragility as result of
loss of functional dystrophin. Loss of sarcolemmal integ-
rity triggers the release of signals from the muscle envir-
onment [62], from the damaged myofiber itself [16] or
from other cell types that are recruited and activated
after damage [19, 20]. These events promote the transi-
ent infiltration of immune cells that are essential for
proper regeneration and participate in satellite cell acti-
vation [49]. However, chronic inflammation in dys-
trophic muscle contributes to disease progression and
dysregulated satellite cell activation, as has also been
proposed for inflammatory myopathies [61]. In Pompe
disease the primary defect is not at the sarcolemma [15]
and an aberrant immune response is generally absent in
Pompe disease [41], indicating that satellite cell function
and activation are differently regulated in Gaa-deficient
muscle. It is tempting to speculate that the lysosomal
damage as result of glycogen accumulation and/or the
subsequent block of autophagy [13, 32] interfere with
satellite cell activation. It has been established that au-
tophagy is crucial for securing the bioenergetics de-
mands associated with satellite cell activation [46].
Deficiency of SIRT1, a nutrient sensor that regulates au-
tophagic flux in satellite cell progeny, was found to delay
satellite cell activation [46]. Inhibition of autophagic flux
has been reported to occur in Gaa−/− myofibers [12, 36],
but whether this affects satellite cell activation remains
to be determined.
Satellite cells in Gaa−/− muscle do not respond to the
progressive tissue damage, in Pompe patients as well as
in mice of 15 weeks and older. Our finding that
experimentally-induced muscle injury evokes an efficient
muscle regenerative response suggests that once satellite
cells are activated, downstream processes such as myo-
genic differentiation and myoblast fusion are unaffected
by Gaa deficiency. This is in agreement with the normal
myogenic differentiation of induced pluripotent stem
cells established from Pompe patients’ fibroblasts, even
those generated from a severely affected classic infantile
patient [60]. We speculate that the maintenance of satel-
lite cell function and number, as well as a functional re-
generation machinery offers opportunities for developing
a muscle regenerative therapy for Pompe disease through
stimulation of endogenous satellite cells. Satellite cells can
be safely and efficiently activated through exercise [45].
Previous exercise programs in our and other centers were
found to be well tolerated by and beneficial for adult
Pompe patients [11, 26, 34, 44, 47, 50]. It can be predicted
that induced satellite cell activation would be less favor-
able in untreated classic infantile patients, since these pa-
tients display severe pathology directly after birth, and
newly regenerated muscle fibers likely develop pathology
rapidly. However, treatment of classic infantile patients
with ERT can significantly improve muscle function and
morphology [53] and delay the severity of symptoms. This
would suggest that combining ERT with induced satellite
cell activation might be beneficial for these patients. The
development of pathology can take years in patients with
a more slowly progressing disease course. Based on our
findings in the mouse model of Pompe disease, restoration
of the muscle condition via induced regeneration would
be predicted to delay disease progression. We consider it
worthwhile to extend research on satellite cell activation
in Pompe disease and other neuromuscular disorders that
harbor functional yet inactive satellite cells. Identification
of additional muscle diseases with such a profile may re-
sult in the development of a more generic therapeutic
strategy. If successful, such strategy would be highly valu-
able given the scarcity of treatment options for neuromus-
cular disorders.
Conclusion
The current study shows that in Gaa−/− mice satellite
cell activation and muscle regeneration was insufficient
to repair the disease-mediated damage, similar as was
observed in human patients. However, Gaa-deficient sat-
ellite cells were intrinsically capable of regenerating
muscle and harbored self-renewal potential. Our findings
suggest that the muscle phenotype in Pompe disease
may be ameliorated by regenerative therapies directed at
satellite cell activation.
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Additional file 1: Figure S1. Reduced fiber diameter in GAAKO animals.
A. Fiber diameter frequency distribution plot of WT(FVB) and Gaa−/−(FVB)
at 15 weeks of age. B. WT(Bl6) and GAAKO(Bl6) at 3 months of age showing
reduced fiber diameter in Gaa−/− (Bl6). These data suggest muscle atrophy is
observed in GAA-deficient animals on both FVB/N and C57/Bl6 backgrounds.
(PDF 122 kb)
Additional file 2: Figure S2. Modest muscle regeneration in Gaa−/−(Bl6)
animals. A.eMyHC staining of QF sections from WT(Bl6) and Gaa−/−(Bl6)
animals. The figure shows selected areas of eMyHC (red)/laminin(green)/
Hoechst(blue) stained QF sections from 4, 12 and 36 week old WT(Bl6)
and Gaa−/− (Bl6) animals. eMyHC-positive were rare and very small in
Gaa−/− (Bl6) muscle, in line with findings in GAA−/−(FVB) (see Fig. 2A).
B. Examples of HE-stained section from GAS muscle from 3 months old
WT(Bl6) and Gaa−/−(Bl6) animals. (PDF 320 kb)
Additional file 3: Figure S3. Satellite cell numbers are increased in
Gaa−/− TA muscle. The number of Pax7-positive cells in 15 week (A) and
25 week (B) WT and Gaa−/− from Fig. 3 expressed as Pax7-positive cells/
myofiber. Data are means ± SD from 2 muscles derived from 2 different ani-
mals per genotype per timepoint. *p < 0.05 and **p < 0.01. (PDF 103 kb)
Additional file 4: Figure S4. Identification of Pax7-positive satellite cells
by flow cytometry. A. Representative dot plots from CD31-APC/CD45-
APC/Sca1-FITC/Vcam-PeCY7 stained muscle cell suspensions according to
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the procedure described previously by Liu et al. [28]. The gating strategy is
depicted by the green arrow. The colors of the box/plot outlines correspond
with the gated populations. Satellite cells are in the CD45neg/CD31neg/sca1-
neg/Vcam-positive gate (green box). B. pax7 (red)/Hoechst(blue) staining of
FACS-sorted satellite cells after 24 h culture using the procedure shown in
(A). The lower panel shows the zoom of the insert in the upper panel.
Counting Pax7 expressing cells indicated that sorting was performed at
> 93% purity. C. Quantification of the percentage of Vcam-positive cells
by flow cytometry. Data from individual mice are plotted as single dots.
(PDF 1056 kb)
Additional file 5: Figure S5. Satellite cell numbers are increased in
Gaa−/−(Bl6) muscle. A. Satellite cells were detected in 3 months old WT(Bl6)
and Gaa−/−(Bl6) gastrocnemius (GAS) cryosections by immunofluorescent
staining of Pax7 (red). Myofibers were visualized using a laminin antibody
(green) and nuclei with Hoechst (blue). White arrows point to Pax7-positive
satellite cells. B. Quantification of A. The figure depicts the mean percentage
of Pax7-positive Satellite cells per field ± SD. C. Western blot analysis of Pax7
expression in GAS muscle from 13 week old WT(Bl6) and Gaa−/−(Bl6)
animals. Western blot analysis was performed as previously described
[14]. (PDF 952 kb)
Additional file 6: Figure S6. Detection of proliferating satellite cells in
GAA-deficient limb muscle. Representative images from TA limb muscle
sections co-stained for Pax7 (red) and Ki67 (green) to detect proliferating
satellite cells (arrow). Nuclei are visualized with Hoechst (blue). The arrowhead
points to a Pax7-positive/Ki67-negative quiescent satellite cell. (PDF 286 kb)
Additional file 7: Figure S7. Detailed histological evaluation of
regenerating WT and Gaa−/− muscle. The figure depicts HE- and
trichrome stained histological sections from 15 week WT(FVB) and
Gaa−/− (FVB) TA muscles at multiple time-points during the first 15 days
after BaCl2-induced muscle regeneration. Gaa
−/− (FVB) muscle regenerates
efficiently and completely (left panels). The trichrome stain shows absence of
residual fibrotic tissue after completing a regeneration cycle (right panels). As
explained in the text WT(FVB) has a regeneration cycle of more than 30 days
and was therefore still actively remodelling at 15 DPI. Arrows point to small
de novo myofibers detected as early as 3 DPI in regenerating Gaa−/−(FVB)
muscle. (PDF 569 kb)
Additional file 8: Figure S8. Gaa−/− muscle regenerates completely
without tissue remodeling Depicted are images from trichrome staining
of TA muscle of WT(FVB) and Gaa−/−(FVB) at 10, 25 and 40 weeks before
and 15 days after BaCl2 injury. (PDF 348 kb)
Additional file 9: Figure S9. Efficient regeneration of GAAKO-muscle
after cardiotoxin-induced injury in GAA-deficient animals on a C57/Bl6
background. The figure shows histological sections from TA HE-stained
sections from 12 and 48 week old WT(Bl6) and Gaa−/− (Bl6) animals at
indicated time points after injury uisng cardiotoxin (CTX)-injection. The
upper panels show HE-stained sections from QF muscle, while the middle
panels show images from regenerating GAS. The lower panels depict
regenerating QF from 11 months old WT(Bl6) and Gaa−/− (Bl6) animals.
These data demonstrate that the capacity to regenerate after experimental
injury is also maintained in GAA-deficient muscle on a C57/Bl6 background.
(PDF 386 kb)
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